T Cell Lymphomas
Conference Coverage
ECHELON-2: BV-CHP boosts survival in PTCL
SAN DIEGO – The newly approved regimen outperformed the standard CHOP regimen in this rare cancer.
News
FDA expands approval of brentuximab vedotin to PTCL
This is the first FDA approval of a treatment for newly-diagnosed PTCL.
Conference Coverage
When to choose stem cell transplant in PTCL
DUBROVNIK, CROATIA – Dr. Ali Bazarbachi gives his tips for when to use allo- versus auto-HSCT in patients with peripheral T-cell lymphomas.
From the Journals
AITL responds to 5-azacytidine in small series
The small study showed high response and no significant safety concerns.
Article
Brentuximab vendotin plus CHP meets PFS endpoint in ECHELON-2
Takeda Pharmaceuticals and Seattle Genetics announced phase 3 trial results in frontline treatment of peripheral T-cell lyphoma (PTCL).
News
FDA lifts partial hold on tazemetostat trials
The partial hold that paused U.S.-based enrollment in clinical trials of tazemetostat has been lifted.
From the Journals
Researchers find drug target in anaplastic large-cell lymphoma
A new study suggests TYK2 is expressed in all cases of ALCL.
News
CPI-613 receives orphan designation for PTCL
The Food and Drug Administration has granted orphan drug designation to CPI-613 for the treatment of peripheral T-cell lymphoma (PTCL).
[[{"...
Article
Make The Diagnosis - September 2018
A 75-year-old man presented with asymptomatic annular plaques on both arms, thighs, abdomen, and buttocks, present for several months.
Conference Coverage
New regimens for youth with T-cell malignancies yield best outcomes yet
More than 8 in 10 youth were still alive and free of disease 4 years after starting combinations of methotrexate and/or nelarabine with chemo.
News
FDA places partial hold on trials after secondary lymphoma
A pediatric patient developed a secondary T-cell lymphoma during a phase 1 trial of tazemetostat.